Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

FDA grants full approval to Travere’s Filspari for rare kidney disease IgA nephropathy

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression

- PMLiVE

J&J presents positive late-stage results for Rybrevant/Lazcluze combination in NSCLC

The chemotherapy-free regimen was approved in the US last month for advanced lung cancer patients

- PMLiVE

Eli Lilly’s once-weekly insulin candidate shows promise in late-stage diabetes trials

It is hoped that a once-weekly treatment option could improve adherence rates

- PMLiVE

What are “orphan drugs” and how do we navigate the challenges of writing about them?

The first in our 'Ask Alex' series, where Principal Medical Writer, Dr Alexandra Loveday answers some frequently asked questions about Medcomms. This week, she takes a look at 'orphan drugs',...

Mednet

- PMLiVE

GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

The chronic respiratory disease affects more than 300 million people globally

- PMLiVE

Pfizer/Valneva share promising results for Lyme disease vaccine candidate

There are currently no approved human vaccines for the bacterial infection

- PMLiVE

Eli Lilly and HAYA Therapeutics enter metabolic condition partnership worth $1bn

The companies will aim to discover regulatory genome targets for obesity and related metabolic conditions

- PMLiVE

Worldwide Clinical Trials appoints Alessandra Vignola as president of cardiovascular and metabolic

Vignola has more than 30 years of experience in the pharmaceutical and clinical research industry

- PMLiVE

New Origins Webinar – ” Why Patient Perspectives Matter: Driving Success in Clinical Trials”

Origins are pleased to announce the first instalment of our Autumn/Winter webinar series! Join us on Tuesday 15th October at 2pm BST as we discuss " Why Patient Perspectives Matter:...

Origins – The Patient Focused Specialists

- PMLiVE

MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

- PMLiVE

MHRA authorises first in new class of treatment for endometriosis symptoms

The chronic condition affects approximately 176 million women worldwide

Biogen Idec building

Biogen shares promising results for higher dose nusinersen in spinal muscular atrophy

The neuromuscular disease affects approximately one in every 10,000 babies worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links